CAS No.:125-33-7

TOXICITY DATA with REFERENCE：

1.		mmo-sat 6666 µg/plate		ENMUDM    Environmental Mutagenesis. 8 (Suppl 7)(1986),1.
2.		cyt-hmn:leu 1 mg/L		AJOGAH    American Journal of Obstetrics and Gynecology. 116 (1973),867.
3.		orl-wmn TDLo:38 g/kg/7Y-I		DICPBB    Drug Intelligence and Clinical Pharmacy. 17 (1983),551.
4.		orl-rat LD50:1500 mg/kg		NIIRDN    “Drugs in Japan. Ethical Drugs, 6th Edition 1982“ Edited by Japan Pharmaceutical Information Center. 6 (1982),691.
5.		ipr-rat LD50:240 mg/kg		PCJOAU    Pharmaceutical Chemistry Journal (English Translation). Translation of KHFZAN. 25 (1991),305.
6.		orl-mus LD50:280 mg/kg		TXAPA9    Toxicology and Applied Pharmacology. 34 (1975),271.
7.		ipr-mus LD50:332 mg/kg		PCJOAU    Pharmaceutical Chemistry Journal (English Translation). Translation of KHFZAN. 15 (1981),403.

child     TDLo     oral   625mg/kg (625mg/kg)   BEHAVIORAL: GENERAL ANESTHETICBEHAVIORAL: SLEEPBEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)   British Medical Journal. Vol. 1, Pg. 90, 1957.
mouse     LD50     intraperitoneal   332mg/kg (332mg/kg)   BEHAVIORAL:   ANTICONVULSANT Pharmaceutical Chemistry Journal Vol. 15, Pg. 403, 1981.
mouse     LD50     oral   280mg/kg (280mg/kg)     Toxicology and Applied Pharmacology. Vol. 34, Pg. 271, 1975.
mouse     LD50     unreported   340mg/kg (340mg/kg)   BEHAVIORAL: ANTICONVULSANT Russian Pharmacology and Toxicology Vol. 43, Pg. 73, 1980.
rat     LD50     intraperitoneal   240mg/kg (240mg/kg)     Pharmaceutical Chemistry Journal Vol. 25, Pg. 305, 1991.
rat     LD50     oral   1500mg/kg (1500mg/kg)     Drugs in Japan Vol. 6, Pg. 691, 1982.
rat     LD50     unreported   > 2gm/kg (2000mg/kg)     British Journal of Pharmacology and Chemotherapy. Vol. 8, Pg. 230, 1953.
women     TDLo     oral   5mg/kg (5mg/kg)   BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)BEHAVIORAL: HEADACHE
GASTROINTESTINAL:   NAUSEA OR VOMITING   Lancet. Vol. 266, Pg. 102, 1954.
women     TDLo     oral   450mg/kg (450mg/kg)   BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)BEHAVIORAL: ATAXIA
BEHAVIORAL:   ANTIPSYCHOTIC Archives of Neurology Vol. 30, Pg. 255, 1974.
women     TDLo     oral   38gm/kg/7Y-I (38000mg/kg)   BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS"BEHAVIORAL:   TOXIC PSYCHOSIS   Drug Intelligence and Clinical Pharmacy. Vol. 17, Pg. 551, 1983.

SAFETY PROFILE：
Poison by ingestion and intraperitoneal routes. Human teratogenic effects include developmental abnormalities of the craniofacial area, skin and skin appendages, and cardiovascular system. Human reproductive effects: effects on newborn, including unusual growth statistics, drug dependence, physical and other neonatal changes. Experimental teratogenic and reproductive effects. Human mutation data reported. An addictive drug. When heated to decomposition it emits toxic fumes of NO_x. See also BARBITURATES.
Hazard Codes:
    Xn: Harmful 
Risk Statements about 2-DESOXYPHENOBARBITAL(125-33-7):
    R22 Harmful if swallowed.
    R40 Limited evidence of a carcinogenic effect.
Safety Statements about 2-DESOXYPHENOBARBITAL(125-33-7):
    S22 Do not breathe dust.
    S36 Wear suitable protective clothing.
    S45 In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)